Annovis Bio Inc expected to post a loss of $1.09 a share - Earnings Preview

Annovis Bio

04/11/2023 01:03

* Annovis Bio Inc  ANVS.N   ANVS.K  is expected to show no
change
in quarterly revenue when it reports  results on November 6
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Annovis Bio Inc is
for a
loss of $1.09 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Annovis Bio
Inc
is $40​, above​ its last closing price of $6.37. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -1.11       -1.14      -1.07     Beat    6.3
 Mar. 31 2023  -0.33       -0.33      -1.19     Missed  -256.3
 Dec. 31 2022  -1.05       -1.05      -0.38     Beat    63.9​
 Sep. 30 2022  -1.02       -1.01      -0.93     Beat    8.2
 ​​Jun.        -0.65       -0.64      -1.07     Missed  -65.9
 30 2022                                                
 Mar. 31 2022  -0.58       -0.58      -0.72     Missed  -24.1​
 Dec. 31 2021  -0.25       -0.25      -0.75     Missed  -200
 Sep. 30 2021  -0.44       -0.44      -0.35     Beat    20.5
 This summary was machine generated November 4 at 01:03 GMT.  All
figures in US dollars  unless otherwise stated